e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study
Lucie Cornet, Charles Khouri, Matthieu Roustit, Christophe Guignabert, Marie-Camille Chaumais, Marc Humbert, Bruno Revol, Fabien Despas, David Montani, Jean-Luc Cracowski
Source:
Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018
Journal Issue:
May
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lucie Cornet, Charles Khouri, Matthieu Roustit, Christophe Guignabert, Marie-Camille Chaumais, Marc Humbert, Bruno Revol, Fabien Despas, David Montani, Jean-Luc Cracowski. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study. Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pathophysiology of central apnoea: how do we distinguish normal from abnormal?
Pathophysiology of pulmonary hypertension: what the interested clinician needs to know
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Related content which might interest you:
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence
Source: Eur Respir J 2010; 36: 709-711
Year: 2010
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Source: Eur Respir Rev 2008; 17: 72-73
Year: 2008
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016
Year: 2017
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source: Eur Respir J 2015; 45: 1303-1313
Year: 2015
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research
Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017
Year: 2017
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept